Further studies which longitudinally investigate for the development of HR gene (e.g.: BRCA1/2, RAD51C/D, PALB2) reversion mutations through a sequential tumour or liquid biopsies are required to comprehensively inform the real-world incidence, timing of development, and impact of such mutations on patient outcomes in clinical settings. This evidence concerns the gene BRCA1 and neoplasm.